CN106478687B - Using 1- (2- pyridines) -9- ethyl-beta-carbolines as the chlorination copper complex and its synthetic method of ligand and application - Google Patents
Using 1- (2- pyridines) -9- ethyl-beta-carbolines as the chlorination copper complex and its synthetic method of ligand and application Download PDFInfo
- Publication number
- CN106478687B CN106478687B CN201610855367.0A CN201610855367A CN106478687B CN 106478687 B CN106478687 B CN 106478687B CN 201610855367 A CN201610855367 A CN 201610855367A CN 106478687 B CN106478687 B CN 106478687B
- Authority
- CN
- China
- Prior art keywords
- compound
- synthetic method
- formula
- polar solvent
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010189 synthetic method Methods 0.000 title claims abstract description 21
- 238000005660 chlorination reaction Methods 0.000 title claims abstract description 5
- 239000003446 ligand Substances 0.000 title abstract description 22
- 150000004699 copper complex Chemical class 0.000 title abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 53
- 150000001875 compounds Chemical class 0.000 claims abstract description 53
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000002798 polar solvent Substances 0.000 claims abstract description 28
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 19
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 7
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 6
- 239000012467 final product Substances 0.000 claims abstract description 4
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000010668 complexation reaction Methods 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 45
- 239000000047 product Substances 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000013078 crystal Substances 0.000 claims description 21
- 239000003960 organic solvent Substances 0.000 claims description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- 239000010949 copper Substances 0.000 claims description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 14
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 claims description 12
- 229940125782 compound 2 Drugs 0.000 claims description 12
- 239000007800 oxidant agent Substances 0.000 claims description 11
- 230000001590 oxidative effect Effects 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 229940125904 compound 1 Drugs 0.000 claims description 8
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical group C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 7
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 claims description 5
- AQZMINLSVARCSL-UHFFFAOYSA-N 4-chloro-3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile Chemical compound ClC1=CC(=O)C(C#N)=C(C#N)C1=O AQZMINLSVARCSL-UHFFFAOYSA-N 0.000 claims description 5
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical class CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 claims description 5
- MSBWDNNCBOLXGS-UHFFFAOYSA-L manganese(2+);diacetate;hydrate Chemical compound O.[Mn+2].CC([O-])=O.CC([O-])=O MSBWDNNCBOLXGS-UHFFFAOYSA-L 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 239000000376 reactant Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 238000006356 dehydrogenation reaction Methods 0.000 claims description 2
- 150000007529 inorganic bases Chemical group 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- JEHCHYAKAXDFKV-UHFFFAOYSA-J lead tetraacetate Chemical compound CC(=O)O[Pb](OC(C)=O)(OC(C)=O)OC(C)=O JEHCHYAKAXDFKV-UHFFFAOYSA-J 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- 229910052697 platinum Inorganic materials 0.000 abstract description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract description 4
- -1 ethyl β carbolines Chemical class 0.000 abstract description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 238000001819 mass spectrum Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000011259 mixed solution Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000005388 borosilicate glass Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 238000001308 synthesis method Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 4
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 4
- 239000011572 manganese Substances 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229940005561 1,4-benzoquinone Drugs 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical group [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- MUQXMFODCOGCJD-UHFFFAOYSA-N CC[n]1c2c(-c3ccccn3)nccc2c2c1cccc2 Chemical compound CC[n]1c2c(-c3ccccn3)nccc2c2c1cccc2 MUQXMFODCOGCJD-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101000905241 Mus musculus Heart- and neural crest derivatives-expressed protein 1 Proteins 0.000 description 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229930002341 quinoline alkaloid Natural products 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention discloses one kind using 1 (2 pyridine) 9 ethyl β carbolines as the chlorination copper complex and its synthetic method of ligand and application.Shown in the structural formula of the complex such as following formula (I), its synthetic method is：Take compound and copper chloride as shown in following formula (II), be dissolved in polar solvent, carry out complexation reaction, to obtain the final product；Wherein, the polar solvent is selected from one or both of methanol and ethanol and the combination more than one or both of water, acetone, chloroform, dichloromethane and N, N dimethylformamide.Complex of the present invention is shown than ligand and the stronger antitumor activity of cis-platinum, is had preferable potential medical value, is expected to be used for the preparation of various antitumor drugs.Structure shown in formula (I) and formula (II) is as follows：
Description
Technical field
The present invention relates to pharmaceutical technology field, and in particular to one kind is using 1- (2- pyridines) -9- ethyl-beta-carbolines as ligand
Chlorination copper complex and its synthetic method and application.
Background technology
B-carboline is a kind of alkaloid for being distributed widely in nature, they are primarily present in a variety of terrestrial plants and ocean
In biology.Chemically classify in structure, beta-carboline alkaloid belongs to indoles alkaloid, it is three be made of trypoline
Member ring systems, its skeleton are a planar molecules, wherein two nitrogen-atoms of 2 and 9 exist with different hybridization states,
9 nitrogen-atoms are sp3Hydridization, for rich pi-electron system, 2 nitrogen-atoms are sp2Hydridization, to lack pi-electron system.Two nitrogen-atoms with
The chemical property and bioactivity of such compound are closely related.There is such compound extensive biology and pharmacology to live
Property, including：Sedative, antianxiety, hypnosis, anti-spasm, antitumor, antiviral, desinsection and antibacterial activity etc..Therefore β-click
Quinoline alkaloid is increasingly paid attention to be subject to researcher.
On the other hand, the Pharmaceutical Inorganic Chemistry based on medical active ligand is studied in recent years with bioinorganic chemistry
Flourish and become hot research field, the first, second and third generation platinum class especially with cis-platinum, carboplatin, oxaliplatin etc. for representative
Successful application of the cancer therapy drug as front-line chemotherapeutic agents, really indicates Metal Drugs research and the arrival of application new era.
But have not yet to see copper chloride (II) complex and its synthetic method using 1- (2- pyridines) -9- ethyl-beta-carbolines as ligand
With the relevant report of application.
The content of the invention
The technical problem to be solved in the present invention is to provide structure it is novel using 1- (2- pyridines) -9- ethyl-beta-carbolines as with
Copper chloride (II) complex of body, and its synthetic method and application.
The present invention relates to compound shown in lower formula (I) or its pharmaceutically acceptable salt：
The synthetic method of compound is shown in above-mentioned formula (I)：Take compound and copper chloride as shown in following formula (II)
(CuCl2·2H2O), it is dissolved in polar solvent, carries out complexation reaction, that is, obtain target product；Wherein, the polar solvent is
Selected from one or both of methanol and ethanol with water, acetone, chloroform, dichloromethane and n,N-Dimethylformamide
One or more kinds of combinations；
Compound shown in raw material formula (II) involved in above-mentioned synthetic method participates in reacting as ligand, its chemical name is
1- (2- pyridines) -9- ethyl-beta-carbolines, in this application also referred to as L.Compound shown in the formula (II) can designed, designed synthesis
Prepared by route, preferably prepared as follows：
Using tryptamines and pyridine-2-formaldehyde as raw material, reacted in the first organic solvent, compound is obtained by dehydrating condensation
1；Then compound 1 is placed in the second organic solvent, add oxidant cyclization and dehydrogenation obtain compound 2 (1- (2- pyridines)-
B-carboline)；Compound 2 is placed in the aprotic polar solvent of alkaline matter again, 1- bromoethanes is added and carries out substitution reaction, i.e.,
；Wherein：
First organic solvent is one kind or two in toluene, methanol, ethanol, dichloromethane and chloroform
The combination of the kind above；
Second organic solvent is one kind or two in benzene, toluene, paraxylene, glacial acetic acid and dichloromethane
The combination of the kind above；
The oxidant is palladium carbon, manganese acetate hydrate (Mn (Ac)3·nH2O), lead tetraacetate (Pb (Ac)4) or 2,3-
Two chloro- 5,6- dicyan 1,4-benzoquinone (DDQ)；
The alkaline matter is inorganic base；
The aprotic polar solvent in N,N-dimethylformamide, dimethyl sulfoxide (DMSO) and acetone one kind or
Two or more combinations.
The synthetic route of compound method is as follows shown in above-mentioned preparation formula (II)：
Reagent：(a) the first organic solvent；(b) oxidant, the second organic solvent；(c) alkaline matter, aprotonic polar are molten
Agent.
The more specifically preparation method of compound shown in above-mentioned formula (II), comprises the following steps：
1. using tryptamines and pyridine-2-formaldehyde as raw material, reacted in the first organic solvent, discharge reaction life in reaction process
Into water, solvent evaporated after question response, obtains compound 1；
2. compound 1 is placed in the second organic solvent, oxidant is added, is reacted under heating condition, question response terminates, mistake
Filter, collects filtrate, is evaporated, obtains compound 2；
3. taking alkaline matter to be dissolved in aprotic polar solvent, then add compound 2 and 1- bromoethanes are reacted, treat
Reaction terminates, and reactant is put into frozen water, gained mixture of ice and water is extracted, collection organic phase, solvent evaporated, to obtain the final product
To compound (i.e. compound 3) shown in formula (II).
Shown in above-mentioned formula (II) the step of compound synthesis method 1. in, the amount of the material of tryptamines and pyridine-2-formaldehyde it
Than being usually 0.8~1.2：1, reaction can carry out under conditions of being heated or not heated, and water knockout drum can be used in reaction process
Whether the water of discharge reaction generation, reaction can use thin-layer chromatography (TLC) tracing detection completely；Preferably, reaction uses
Heating reflux reaction, the time control reacted at this time are appropriate in 2~6h.In the step, what is obtained is the thick production of compound 1
Thing, in order to reduce the impurity in subsequent reactions, improves the yield of postorder reaction, preferably to residue obtained progress purification process after
Postorder reaction is carried out again.Specific purification process can be recrystallized to residue obtained with small polar solvent, gained recrystallization production
Thing is used further to postorder reaction.It is described be used for recrystallize small polar solvent it is same as the prior art, can be specifically petroleum ether and/
Or n-hexane etc..
Shown in above-mentioned formula (II) the step of compound synthesis method 2. in, reaction preferably use heating reflux reaction, reaction
Whether thin-layer chromatography tracing detection be able to can be used completely.In the step, what is obtained is the crude product of compound 2, in order to reduce
Impurity in subsequent reactions, improves the yield of postorder reaction, preferably to carrying out postorder again after residue obtained progress purification process
Reaction.Specific purification process can be to it is residue obtained with selected from one or both of methanol, ethanol and dichloromethane with
On combination solvent recrystallized, or residue obtained upper silica gel column chromatography is purified, it is used in upper silica gel column chromatography
Eluant, eluent press 6 for petroleum ether and dichloromethane：1~1：The mixed solvent of 1 volume ratio composition.
Shown in above-mentioned formula (II) the step of compound synthesis method 2. in, according to the difference of oxidant, select different
Two organic solvents, it is specific as follows：
(1) when the selected as palladium carbon of oxidant, the second organic solvent is preferably one kind in benzene, toluene and paraxylene
Or two or more combinations, during combination more than the selected as above two of two organic solvents, proportioning between them can be with
For any proportioning.The palladium carbon can be 5%Pd/C or 10%Pd/C, and the addition of the palladium carbon usually presses 10mmol chemical combination
Thing 1 adds 2~4g palladium carbons and calculates.
(2) when the selected as manganese acetate hydrate or lead tetraacetate of oxidant, the second organic solvent is preferably glacial acetic acid；
The addition of the manganese acetate hydrate or lead tetraacetate is usually 2~8 times of the amount of 1 material of compound.When the choosing of oxidant
When being selected as manganese acetate hydrate or lead tetraacetate, pH >=7 of lye regulation system are preferably used after reaction, then it is extracted
Take, collect organic phase, the upper silica gel column chromatography purifying again of the residue obtained by solvent evaporated；Wherein, the lye can be ammonium hydroxide,
The aqueous solution of the alkaline matters such as sodium acetate, sodium carbonate, sodium phosphate, sodium acid carbonate or potassium carbonate, the concentration of the lye is preferably 5
~30w/w%；Solvent for system after extraction tune pH value can be specifically ethyl acetate, dichloromethane, chloroform or ether etc..
(3) when the selected as 2 of oxidant, during chloro- 5, the 6- dicyan 1,4-benzoquinone of 3- bis-, the second organic solvent is preferably benzene, first
One or more kinds of combinations of benzene and dichloromethane, during combination more than the selected as above two of two organic solvents,
Proportioning between them can be any proportioning.The addition of the chloro- 5,6- dicyan 1,4-benzoquinone of 2,3- bis- is usually compound 1
1~4 times of the amount of material.
Shown in above-mentioned formula (II) the step of compound synthesis method 3. in, the alkaline matter, compound 2 and 1- bromoethanes
The ratio between the amount of material be usually 1~4：1：1~3, alkaline matter therein can be further sodium hydride, calcium hydride, hydrogen-oxygen
Change combination more than one or both of calcium, sodium hydroxide, potassium hydroxide, cesium carbonate and potassium carbonate, when the choosing of alkaline matter
During the combination being selected as more than above two, the proportioning between them can be any proportioning.In the step, reaction can 0~
Carried out under the conditions of 80 DEG C, whether reaction can use thin-layer chromatography (TLC) tracing detection completely；Preferably, react 20~
50 DEG C, the time control reacted at this time is appropriate in 1~6h.The solvent extracted to mixture of ice and water can be specifically acetic acid
The conventional extraction solvent such as ethyl ester, dichloromethane, chloroform, petroleum ether or ether.
(such as the first organic solvent, second have involved various solvents in compound synthesis method shown in above-mentioned formula (II)
Solvent and aprotic polar solvent etc.) dosage, so as to dissolve participated in each step reaction raw material be advisable.
What the above method was prepared is the crude product of compound shown in formula (II), in order to further improve shown in formula (II)
The purity of compound, is more advantageous to the progress of subsequent reactions, is used again after preferably carrying out purification process to above-mentioned gained crude product
In the synthetic method of target product of the present invention.The purification process is same as the prior art, can be specifically by crude product
Upper silica gel column chromatography purifying, to obtain pure compounds shown in formula (II)；In upper silica gel column chromatography, eluant, eluent used is two
Chloromethanes and methanol press 1000：1~50：The mixed solvent of 1 volume ratio composition.
In the synthetic method of compound shown in formula (I) of the present invention, in the composition of polar solvent, methanol or ethanol or
Person is that the combination of methanol and ethanol ratio shared in polar solvent is preferably 50~98v/v%；When containing in polar solvent
During two or more selections in water, acetone, chloroform, dichloromethane and n,N-Dimethylformamide, do not surpass in their total amount
Go out under 50% precondition, their proportioning can be any proportioning.The dosage of the polar solvent can determine as needed,
Under normal conditions, compound shown in the copper chloride of 1mmol and 1mmol formulas (II) is dissolved with the polar solvent of 5~80mL.Having
In the dissolving step of body, additive polarity solvent again after generally compound shown in copper chloride and formula (II) is mixed；Also can be by copper chloride
Dissolved respectively with polar solvent with compound shown in formula (II), remix and react together.
In the synthetic method of compound shown in formula (I) of the present invention, compound shown in the copper chloride and formula (II)
The ratio between amount of material can be 1~6：1.
Compound shown in formula (I) of the present invention specifically in synthesis, can use normal pressure solwution method or high pressure solvent heat
Method is synthesized.
When using normal pressure solwution method, its synthetic method includes：Compound shown in formula (II) and copper chloride are taken, is dissolved in polarity
In solvent, gained mixed liquor reacts under the conditions of being heated or not heated, and reactant removes partial solvent, stands, and separates out, isolates
Crystal, up to target product.
In above-mentioned normal pressure solwution method, reaction can carry out in 20 DEG C to polar solvent of reflow temperature range, preferably adopt
With back flow reaction, further preferably reaction is carried out in 50 DEG C to polar solvent of reflow temperature range, more preferably 60
Reacted under the conditions of DEG C.Whether reaction can use thin-layer chromatography tracing detection completely.In this method, product is generally in the form of crystal
A large amount of generations, if the addition of polar solvent is larger in previous step (such as the upper limit close to proportioning) or solvent is to the molten of product
Solution property is preferable, then solution may be in clear state after reacting, this is because the product formed is precipitated dissolves institute by polar solvent
Cause, gained reaction solution can be concentrated or is evaporated under reduced pressure to remove partial solvent at this time, typically concentration removes polar solvent and adds
The 50~90% of amount.Isolated solid can be washed further with ether, acetone, ethanol, methanol or dichloromethane, it
It is dried again afterwards.
When the hot method of high pressure solvent, its synthetic method includes：Compound shown in formula (II) and copper chloride are taken, it is molten to be dissolved in polarity
In agent, gained mixed liquor is placed in container, and vacuum is evacuated to after liquid nitrogen frozen, sealing, then anti-under the conditions of 30~140 DEG C
Should, obtain target product.
In the above-mentioned hot method of high pressure solvent, the container is usually heavy wall borosilicate glass tube, is reacted usually at 30~140 DEG C
Under the conditions of carry out, under this temperature conditions, the time of reaction is preferably controlled in 2~24h, can also be extended to according to actual conditions
More than 24h.Further preferred mixed solution is reacted under the conditions of 50~140 DEG C, more preferably mixed solution be 80~
Reacted under the conditions of 100 DEG C.When being carried out under room temperature or heating condition of the reaction below 80 DEG C, when reaction needs longer
Between can just obtain higher yield.
Present invention additionally comprises compound or its pharmaceutically acceptable salt shown in above-mentioned formula (I) in antitumor drug is prepared
Application.
Present invention additionally comprises what is prepared using compound or its pharmaceutically acceptable salt shown in above-mentioned formula (I) as active ingredient
Antitumor drug.
Compared with prior art, the present invention provides a kind of new using 1- (2- pyridines) -9- ethyl-beta-carbolines as ligand
Copper chloride (II) complex, and its synthetic method and application.Applicant is by investigating its suppression to various tumor cell strains
Make and use, the results showed that the complex has stronger anti tumor activity in vitro, and apparently higher than cis-platinum, has preferable potential
Medical value, is expected to be used for the preparation of various antitumor drugs.
Brief description of the drawings
Fig. 1 is the x-ray crystal structure figure of final product made from the embodiment of the present invention 5.
Embodiment
With reference to specific embodiment, the present invention is described in further detail, to more fully understand present disclosure, but
The present invention is not limited to following embodiments.
Embodiment 1：The synthesis of compound, that is, 1- (2- pyridines) -9- ethyl-beta-carbolines (L) shown in formula (II)
1) 1.6g (10mmol) tryptamines, 1.1g (10mmol) pyridine-2-formaldehydes and 50ml toluene are added 150ml round bottoms to burn
Bottle, plus water knockout drum, condenser pipe group component water reflux, be heated to reflux 4 it is small when, solvent evaporated after question response, residue
Compound 1 (2.3g, yield 92%) is recrystallized to give with 100ml n-hexanes；
2) 2.5g (10mmol) compound 1,2.5g palladium carbons (10%Pd/C) and 100ml paraxylene are added into 250ml circles
Bottom flask, is heated to flowing back, and is terminated with thin-layer chromatography tracing detection to reaction, stands and filters and be evaporated filtrate, gained is residual
Silica gel column chromatography purifies (V on slagPetroleum ether：VDichloromethane=1:1) compound 2 (2.1g, yield 86%), is obtained；
3) 0.24g (10mmol) sodium hydrides and 15ml n,N-Dimethylformamide are added to 50ml round-bottomed flasks, room temperature
Stirring 10 minutes, adds 2.5g (10mmol) compound 2 and 10mmol 1- bromoethanes, and with thin-layer chromatography tracing detection extremely
Reaction terminates, and then puts into reaction solution in 500ml frozen water, with the extraction of 100ml ethyl acetate three times, merges organic phase, is evaporated
Solvent, residue obtained upper silica gel column chromatography purifying (VDichloromethane：VMethanol=100:1) compound 3 (2.2g, yield 81%), is obtained.
Products therefrom is characterized：
(1) nuclear magnetic resonance spectroscopy and carbon spectrum, their spectral data are as follows：
1H NMR(500MHz,CDCl3) δ 8.74 (d, J=4.8Hz, 1H), 8.53 (d, J=5.1Hz, 1H), 8.16 (d, J
=7.8Hz, 1H), 8.02 (d, J=5.1Hz, 1H), 7.92 (d, J=7.6Hz, 1H), 7.88 (td, J=7.6,1.7Hz, 1H),
7.57 (t, J=7.7Hz, 1H), 7.45 (d, J=8.3Hz, 1H), 7.39-7.35 (m, 1H), 7.28 (t, J=7.5Hz, 1H),
4.18 (q, J=7.1Hz, 2H), 1.02 (t, J=7.2Hz, 3H)
13C NMR(126MHz,CDCl3)δ158.89,148.53,142.65,142.16,138.22,137.09,
134.24,131.42,128.69,125.07,123.31,121.72,121.63,119.98,114.78,110.26,40.13,
14.05.
(2) high resolution mass spectrum, ESI-MS m/z:274.1[M+H]+.
Accordingly, it can be determined that above-mentioned product is 1- (2- pyridines) -9- ethyl-beta-carbolines, its chemical structural formula such as following formula
(II) shown in：
Embodiment 2：The synthesis of ligand L
Embodiment 1 is repeated, unlike：
In step 2), with Mn (Ac)3Instead of palladium carbon, paraxylene, control Mn (Ac) are replaced with glacial acetic acid3Addition be
2 times of the amount of 1 material of compound, react and are carried out under the conditions of 70 DEG C, and TLC tracing detections to reaction terminate, then will with ammonium hydroxide
The pH of system is adjusted to 7, then is extracted with ethyl acetate three times, merges organic phase, solvent evaporated, residue obtained upper silicagel column (chromatography
Purify (VPetroleum ether：VDichloromethane=1:1) compound 2, is obtained.
Nuclear magnetic resonance spectroscopy, carbon-13 nmr spectra and high resolution mass spectrum analysis are carried out to the present embodiment products therefrom, is determined
For target product 1- (2- pyridines) -9- ethyl-beta-carbolines.
Embodiment 3：The synthesis of ligand L
Embodiment 2 is repeated, unlike：
In step 2), with Pb (Ac)4Instead of Mn (Ac)3, control Pb (Ac)4Addition for 1 material of compound amount 5
Times, react and carried out under the conditions of 60 DEG C.
Nuclear magnetic resonance spectroscopy, carbon-13 nmr spectra and high resolution mass spectrum analysis are carried out to the present embodiment products therefrom, is determined
For target product 1- (2- pyridines) -9- ethyl-beta-carbolines.
Embodiment 4：The synthesis of ligand L
Embodiment 1 is repeated, unlike：
In step 2), palladium carbon is replaced with chloro- 5, the 6- dicyan 1,4-benzoquinone of 2,3- bis-, paraxylene is replaced with dichloromethane, 2,
The addition of the chloro- 5,6- dicyan 1,4-benzoquinone of 3- bis- is equal with the amount of the material of compound 1.
Nuclear magnetic resonance spectroscopy, carbon-13 nmr spectra and high resolution mass spectrum analysis are carried out to the present embodiment products therefrom, is determined
For target product 1- (2- pyridines) -9- ethyl-beta-carbolines.
Embodiment 5：Title complex [Cu (L) Cl2] synthesis
In the heavy wall borosilicate glass tube being open at one end, 0.1mmol CuCl are directly added into2·2H2O and 0.1mmol ligands
L, adding 0.6ml ethanol/methylenes mixed solution, (volume ratio of methanol and dichloromethane is 3:1), in the bar vacuumized
Under part, openend is sealed, then when fully reaction 20 is small under the conditions of 50 DEG C, obtains green crystal type solid product.
Products therefrom is characterized：
(1) high resolution mass spectrum, ESI-MS m/z:449[Cu(L)(DMSO)Cl]+(DMSO is used when coming from mass spectrometric measurement
Solvent)
(2) X-ray single crystal diffraction is analyzed, as shown in Figure 1.
Therefore can determine that above-mentioned product is copper (II) complex using 1- (2- pyridines) -9- ethyl-beta-carbolines as ligand
That is title complex [Cu (L) Cl2], shown in its structural formula such as following formula (I)：
Embodiment 6：Title complex [Cu (L) Cl2] synthesis
In the heavy wall borosilicate glass tube being open at one end, 0.2mmol CuCl are directly added into2·2H2O and 0.1mmol ligands
L, adding 0.6ml ethanol/chloroform mixed solution, (volume ratio of ethanol and chloroform is 3:1), under conditions of vacuumizing, will open
Mouth end sealing, then when fully reaction 12 is small under the conditions of 80 DEG C, obtains green crystal type solid product.
Products therefrom carries out structure determination by high resolution mass spectrum and the analysis of X-ray single crystal diffraction, is determined as target cooperation
Thing [Cu (L) Cl2]。
Embodiment 7：Title complex [Cu (L) Cl2] synthesis
In the heavy wall borosilicate glass tube being open at one end, 0.3mmol CuCl are directly added into2·2H2O and 0.1mmol ligands
Abbreviation L, adds 0.6ml methanol/ethanols/N,N-dimethylformamide mixed solution (methanol, ethanol and N, N- dimethyl formyl
The volume ratio of amine is 5：1：1), under conditions of vacuumizing, openend is sealed, then fully reaction 4 is small under the conditions of 100 DEG C
When, obtain green crystal type solid product.
Products therefrom carries out structure determination by high resolution mass spectrum and the analysis of X-ray single crystal diffraction, is determined as target cooperation
Thing [Cu (L) Cl2]。
Embodiment 8：Title complex [Cu (L) Cl2] synthesis
In the heavy wall borosilicate glass tube being open at one end, 0.4mmol CuCl are directly added into2·2H2O and 0.1mmol ligands
L, adding 0.6ml ethanol/acetones mixed solution, (volume ratio of ethanol and acetone is 10:1), will, under conditions of vacuumizing
Openend seals, and then when fully reaction 4 is small under the conditions of 80 DEG C, obtains green crystal type solid product.
Products therefrom carries out structure determination by high resolution mass spectrum and the analysis of X-ray single crystal diffraction, is determined as target cooperation
Thing [Cu (L) Cl2]。
Embodiment 9：Title complex [Cu (L) Cl2] synthesis
Take 6mmol CuCl2·2H2O and 1mmol ligand Ls are placed in round-bottomed flask, are added 80ml ethanol/waters thereto and are mixed
Closing solution, (volume ratio of second alcohol and water is 1:1), after stirring and dissolving, be heated to 60 DEG C reaction 12 it is small when, reactant is concentrated under reduced pressure
Partial solvent is removed, is stood, is had green crystal precipitation, isolate solid, washed with ethanol, it is dry, obtain green crystal.
Products therefrom carries out structure determination by high resolution mass spectrum and the analysis of X-ray single crystal diffraction, is determined as target cooperation
Thing [Cu (L) Cl2]。
Embodiment 10：Title complex [Cu (L) Cl2] synthesis
Take 2mmol CuCl2·2H2O and 1mmol ligand Ls are placed in round-bottomed flask, add thereto 50ml methanol/acetones/
(volume ratio of methanol, acetone and water is 30 to water mixed solution：1：10), after stirring and dissolving, be heated to 50 DEG C reaction 12 it is small when, instead
Answer thing to be concentrated under reduced pressure and remove partial solvent, stand, have green crystal precipitation, isolate solid, washed with ethanol, it is dry, obtain
Green crystal.
Products therefrom carries out structure determination by high resolution mass spectrum and the analysis of X-ray single crystal diffraction, is determined as target cooperation
Thing [Cu (L) Cl2]。
Embodiment 11：Title complex [Cu (L) Cl2] synthesis
Take 3mmol CuCl2·2H2O and 1mmol ligand Ls are placed in round-bottomed flask, add 30ml methanol/chloroform thereto
(volume ratio of methanol and chloroform is 1 to mixed solution：1), after stirring and dissolving, when 20 DEG C of reactions 18 are small, reactant is concentrated under reduced pressure
Partial solvent is removed, is stood, is had green crystal precipitation, isolate solid, washed with ethanol, it is dry, obtain green crystal.
Products therefrom carries out structure determination by high resolution mass spectrum and the analysis of X-ray single crystal diffraction, is determined as target cooperation
Thing [Cu (L) Cl2]。
In order to absolutely prove purposes of the complex of the present invention in pharmacy, applicant has carried out extracorporeal anti-tumor to it
Activity experiment.
Experimental example 1：Copper (II) complex using 1- (2- pyridines) -9- ethyl-beta-carbolines as ligand (presses the embodiment of the present invention
5 the methods are made) and ligand L (being made by 1 the method for the embodiment of the present invention) a variety of human tumor strains are pressed down in vitro
Activity experiment processed
1st, cell line and cell culture
This experiment selects gastric carcinoma cells MGC-803, human hepatoma cell strain Hep G2, human bladder cancer cell T-24, people non-
Small cell lung cancer cell NCI-H460 and human normal cell line HL-7702 totally 5 kinds of cell lines.
All tumor cell lines are cultivated containing 10wt% small ox bloods, 100U/mL penicillin, 100U/mL streptomysins
In RPMI-1640 nutrient solutions, 37 DEG C of 5%CO containing volumetric concentration are put2Cultivated in incubator；Human normal cell line strain then cultivate containing
The small ox bloods of 10wt%, 100U/mL penicillin, 100U/mL streptomysins DMEM nutrient solutions in.
2nd, the preparation of testing compound
The DMSO liquid storages (concentration 0.002mol/L) of each testing compound are diluted successively by RMPI1640 culture mediums
It is respectively 20,10,5,2.5,1.25 μm of ol/L, wherein cosolvent DMSO final concentration≤1% into five concentration gradients.Survey first
Each testing compound of 20 μm of ol/L is tried for the inhibiting rate of tumor cell proliferation, is considered as primary dcreening operation result；Test is different respectively again
Each testing compound is to the Proliferation Ability degree of various tumour cells under gradient concentration, to the Fitting Calculation half-inhibition concentration,
That is IC50Value.
3rd, cell growth inhibition test (mtt assay)
(1) take the logarithm the tumour cell in growth period, after Trypsin Induced, matched somebody with somebody with the nutrient solution containing 10% calf serum
The cell suspension that concentration is 5000/mL is made, is inoculated in every 190 μ L of hole in 96 well culture plates, makes cell density to be measured extremely
1000~10000/hole (edge hole is filled with sterile PBS)；
(2) 5%CO2, 37 DEG C of incubation 24h, are paved with bottom hole to cell monolayer, the medicine 10 of a certain concentration gradient are added per hole
μ L, each concentration gradient set 4 multiple holes；
(3) 5%CO2, when 37 DEG C of incubations 48 are small, observed under inverted microscope；
(4) the MTT solution (5mg/mL PBS, i.e. 0.5%MTT) of 10 μ L is added per hole, continues to cultivate 4h；
(5) culture is terminated, carefully sucks nutrient solution in hole, 150 μ L DMSO are added per hole and fully dissolve first a ceremonial jade-ladle, used in libation precipitation, are shaken
Swing after device mixes, with wavelength be 570nm in microplate reader, reference wavelength measures the OD value in each hole for 450nm；
(6) while zeroing hole (culture medium, MTT, DMSO) is set, (the medicine dissolving of cell, same concentrations is situated between control wells
Matter, nutrient solution, MTT, DMSO).
(7) according to the OD value (OD values) measured, to judge living cells quantity, OD values are bigger, and cytoactive is stronger.
Calculate the inhibiting rate of compound on tumor cell growth.For cell of the inhibiting rate more than 50% under primary dcreening operation concentration
Strain, is further fitted the inhibiting rate data of five concentration gradients by SPSS softwares, obtains compound to different tumours
Half-inhibition concentration (the IC of strain50Value, unit μm ol/L), IC of the compound for different cell lines50Value is as shown in table 1.
Table 1：IC of the compound of the present invention to 5 kinds of cell lines50It is worth (μm ol/L)
From the point of view of anti tumor activity in vitro test result, complex of the present invention has stronger antitumor activity, its
Activity is substantially better than cis-platinum, is expected to exploitation into antitumor drug.
Claims (10)
1. compound shown in lower formula (I)：
2. the synthetic method of compound described in claim 1, it is characterised in that：Take compound and chlorination as shown in following formula (II)
Copper, is dissolved in polar solvent, carries out complexation reaction, that is, obtains target product；Wherein, the polar solvent be selected from methanol and
One or both of ethanol with selected from one or both of water, acetone, chloroform, dichloromethane and n,N-Dimethylformamide
Combination above；
3. synthetic method according to claim 2, it is characterised in that：Compound shown in formula (II) and copper chloride are taken, is dissolved in
In polar solvent, gained mixed liquor reacts under the conditions of being heated or not heated, and reactant removes partial solvent, stands, and separates out, point
Crystal is separated out, up to target product.
4. synthetic method according to claim 3, it is characterised in that：React the reflux temperature model at 50 DEG C to polar solvent
Enclose interior progress.
5. synthetic method according to claim 2, it is characterised in that：Compound shown in formula (II) and copper chloride are taken, is dissolved in
In polar solvent, gained mixed liquor is placed in container, and vacuum is evacuated to after liquid nitrogen frozen, sealing, then in 30~140 DEG C of conditions
Lower reaction, obtains target product.
6. synthetic method according to claim 5, it is characterised in that：Reaction carries out under the conditions of 50~140 DEG C.
7. the synthetic method according to any one of claim 2~6, it is characterised in that：Compound shown in the formula (II)
Prepared as follows：
Using tryptamines and pyridine-2-formaldehyde as raw material, reacted in the first organic solvent, compound 1 is obtained by dehydrating condensation；So
Compound 1 is placed in the second organic solvent afterwards, oxidant cyclization is added and dehydrogenation obtains compound 2；Compound 2 is placed in again
In the aprotic polar solvent of alkaline matter, add 1- bromoethanes and carry out substitution reaction, to obtain the final product；Wherein：
First organic solvent be selected from one or both of toluene, methanol, ethanol, dichloromethane and chloroform with
On combination；
Second organic solvent be selected from one or both of benzene, toluene, paraxylene, glacial acetic acid and dichloromethane with
On combination；
The oxidant is palladium carbon, manganese acetate hydrate, lead tetraacetate or the chloro- 5,6- dicyan 1,4-benzoquinone of 2,3- bis-；
The alkaline matter is inorganic base；
The aprotic polar solvent is selected from one or both of N,N-dimethylformamide, dimethyl sulfoxide (DMSO) and acetone
Combination above；
The structure difference of the compound 1 and compound 2 is as follows：
8. synthetic method according to claim 7, it is characterised in that：Purifying behaviour is carried out to compound shown in gained formula (II)
Make.
9. application of the compound described in claim 1 in antitumor drug is prepared.
A kind of 10. antineoplastic pharmaceutical compositions, it is characterised in that：Contain compound described in claim 1 as active component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610855367.0A CN106478687B (en) | 2016-09-26 | 2016-09-26 | Using 1- (2- pyridines) -9- ethyl-beta-carbolines as the chlorination copper complex and its synthetic method of ligand and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610855367.0A CN106478687B (en) | 2016-09-26 | 2016-09-26 | Using 1- (2- pyridines) -9- ethyl-beta-carbolines as the chlorination copper complex and its synthetic method of ligand and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106478687A CN106478687A (en) | 2017-03-08 |
| CN106478687B true CN106478687B (en) | 2018-05-11 |
Family
ID=58268020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610855367.0A Active CN106478687B (en) | 2016-09-26 | 2016-09-26 | Using 1- (2- pyridines) -9- ethyl-beta-carbolines as the chlorination copper complex and its synthetic method of ligand and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106478687B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107827913B (en) * | 2017-11-23 | 2020-01-10 | 天津师范大学 | 1, 10-phenanthroline-containing N-heterocyclic carbene copper (I) complex and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1500789A (en) * | 2002-11-19 | 2004-06-02 | 北京大学 | Complex ML(DCA) of copper(II), gallium(III) and rare earth ion(Ln**) containing non-methyl canthridic acid radical |
| EP2508570A2 (en) * | 2009-12-02 | 2012-10-10 | SFC Co., Ltd. | Organic metal dye, and photoelectric element and dye-sensitized solar cell using the organic metal dye |
| CN103254239A (en) * | 2013-03-20 | 2013-08-21 | 中山大学 | aryl ruthenium-beta-carboline complex and its preparation method and application |
-
2016
- 2016-09-26 CN CN201610855367.0A patent/CN106478687B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1500789A (en) * | 2002-11-19 | 2004-06-02 | 北京大学 | Complex ML(DCA) of copper(II), gallium(III) and rare earth ion(Ln**) containing non-methyl canthridic acid radical |
| EP2508570A2 (en) * | 2009-12-02 | 2012-10-10 | SFC Co., Ltd. | Organic metal dye, and photoelectric element and dye-sensitized solar cell using the organic metal dye |
| CN103254239A (en) * | 2013-03-20 | 2013-08-21 | 中山大学 | aryl ruthenium-beta-carboline complex and its preparation method and application |
Non-Patent Citations (2)
| Title |
|---|
| 3_甲基_咔啉衍生物的合成及其抑菌活性研究;张前亮;《西北农林科技大学硕士学位论文》;20131231;第1-2章 * |
| Copper(II/I) complexes of 5-pyridin-2-yl-[1,3]dioxolo[4,5-g] isoquinoline: Synthesis, crystal structure, antitumor activity and DNA interaction;Ke-Bin Huang et al;《European Journal of Medicinal Chemistry》;20131231;第70卷;第640-648页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106478687A (en) | 2017-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106632424B (en) | Using 1- (2- pyridines) -9- benzyls-B-carboline as the chlorination copper complex and its synthetic method of ligand and application | |
| CN106632420B (en) | Using 1- (2- pyridines) -9- butyl-ss-carbolines as the chlorination copper complex and its synthetic method of ligand and application | |
| CN106478692B (en) | Using 1 (2 pyridine) 9 benzyl β carbolines as the copper-nitrate complex and its synthetic method of part and application | |
| CN106632421B (en) | The copper-nitrate complex and its synthetic method of 1- (2- pyridines) -9- (4- methylbenzyls)-B-carboline and application | |
| CN106478687B (en) | Using 1- (2- pyridines) -9- ethyl-beta-carbolines as the chlorination copper complex and its synthetic method of ligand and application | |
| CN106478690B (en) | The chlorination copper complex and its synthetic method of 1- (2- pyridines) -9- (4- phenyl butyls)-B-carboline and application | |
| CN106478688B (en) | Using 1- (2- pyridines) -9- methyl-ss-carbolines as the chlorination copper complex and its synthetic method of ligand and application | |
| CN106478689B (en) | The chlorination copper complex of 1- (2- pyridines) -9- (4- methyl-benzyls)-B-carboline and its synthetic method and application | |
| CN106478684B (en) | Using 1- (2- pyridines) -9- heptyl-B-carboline as the chlorination copper complex and its synthetic method of ligand and application | |
| CN106478686B (en) | Using 1 (2 pyridine) 9 ethyl β carbolines as the copper-nitrate complex and its synthetic method of part and application | |
| CN106478685B (en) | Using 1- (2- pyridines) -9- propyl-B-carboline as the chlorination copper complex and its synthetic method of ligand and application | |
| CN106478683B (en) | Using 1- (2- pyridines) -9- isobutyl groups-B-carboline as the chlorination copper complex and its synthetic method of ligand and application | |
| CN106478682B (en) | The chlorination copper complex and its synthetic method of 1- (2- pyridines) -9- (4- luorobenzyls)-B-carboline and application | |
| CN106432289B (en) | Using 1 (2 pyridine) 9 amyl group β carbolines as the chlorination copper complex and its synthetic method of part and application | |
| CN106478691B (en) | The chlorination copper complex and its synthetic method of 1- (2- pyridines) -9- (2- phenylethyls)-B-carboline and application | |
| CN106632416B (en) | Using 1- (2- pyridines) -9- isopentyl-B-carboline as the chlorination copper complex and its synthetic method of ligand and application | |
| CN106632418B (en) | Using 1- (2- pyridines) -9- octyls-B-carboline as the chlorination copper complex and its synthetic method of ligand and application | |
| CN106632419B (en) | Using 1- (2- pyridines) -9- hexyls-B-carboline as the chlorination copper complex and its synthetic method of ligand and application | |
| CN106632422B (en) | The chlorination copper complex and its synthetic method of 1- (2- pyridines) -9- (3- phenyl propyls)-B-carboline and application | |
| CN106632423B (en) | The copper-nitrate complex and its synthetic method of 1- (2- pyridines) -9- (2- phenylethyls)-B-carboline and application | |
| CN106478681B (en) | The copper-nitrate complex and its synthetic method of 1- (2- pyridines) -9- (4- luorobenzyls)-B-carboline and application | |
| CN106478680B (en) | The chlorination copper complex and its synthetic method of 1- (2- pyridines) -9- Cvclopropvlmethvls-B-carboline and application | |
| CN106632414B (en) | The chlorination copper complex of 1 (2 pyridine) 9 (2 ethoxyethyl group) β carbolines and synthetic method and application | |
| CN106478675B (en) | The chlorination copper complex of 1 (2 pyridine) 9 (2 Benzyloxyethyl) β carbolines and synthetic method and application | |
| CN106632415B (en) | The chlorination copper complex of 1 (2 pyridine) 9 (methyl of naphthalene 2) β carbolines and its synthetic method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |